Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim’s BI 882370
Xynomic Pharma announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim, a…
Read More...
Read More...